Patients paid less money out of pocket for naloxone from 2018 through 2022, according to a new analysis published in JAMA. The research, which was based on data from the IQVIA Longitudinal Prescription database, revealed that the mean out-of-pocket cost per prescription declined from $22.51 in 2018 to $10.02 in 2022.

Incorporating an additional 6 years of data, researchers updated a previously published analysis of gabapentinoid use among Americans.

A global increase in severe antimicrobial-resistant fungal infections of the skin—partly due to inappropriate use of topical antifungals and antifungal-corticosteroid combinations—has found its way to the United States.

Both buprenorphine and methadone treat OUD, but there is limited understanding of how in-utero exposure affects infants. Researchers of a new study published in JAMA Internal Medicine used Medicaid data to gauge the risk of congenital malformations in neonates whose mothers received buprenorphine or methadone while carrying them.

FDA added a boxed warning to the osteoporosis drug denosumab (Prolia). The agency’s review of the drug indicated risks that warrant new prescribing information. For patients with chronic kidney disease (CKD)—especially those on dialysis or those with a concomitant diagnosis of mineral and bone disorder—FDA said they could develop severe hypocalcemia, or very low levels of calcium in the blood.